Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a bullish view: Teva has a “Moderate Buy” consensus, with nine buy ratings and one hold. The average 12-month price target is $42.89, while UBS recently raised its target to $48.
• Shares were trading at $36.36, near the top of their 52-week range, with a market capitalization of approximately $42.37 billion. Teva reported quarterly revenue of $4.14 billion and earnings of $0.02 per share.
• Insider activity was a cautionary signal: An executive sold 106,563 shares worth about $3.63 million, and insiders own just 0.54% of the company. Institutional investors, by contrast, hold approximately 54.05% of Teva’s stock.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $42.8889.

Several research analysts recently weighed in on TEVA shares. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an "overweight" rating in a research report on Tuesday, July 28th. UBS Group upped their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Friday. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, August 21st. Finally, Wall Street Zen cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th.

Teva Pharmaceutical Industries Trading Down 0.7%

NYSE TEVA opened at $36.36 on Friday. Teva Pharmaceutical Industries has a 1 year low of $18.21 and a 1 year high of $38.37. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The company has a market capitalization of $42.37 billion, a PE ratio of 60.60, a P/E/G ratio of 4.57 and a beta of 0.87. The company has a fifty day moving average of $34.64 and a 200 day moving average of $33.28.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. Research analysts forecast that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the transaction, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.54% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth $25,000. Cornerstone Planning Group LLC lifted its holdings in Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after purchasing an additional 755 shares in the last quarter. Allworth Financial LP grew its position in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after purchasing an additional 329 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock worth $32,000 after purchasing an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC increased its stake in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after purchasing an additional 292 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source